Brachytherapy for prostate cancer: High dose rate or low-dose rate?;Curiethérapie du cancer prostatique: Haut débit ou bas débit de dose?

Cancer/Radiotherapie

Volumn 9, Issue 8, 2005, Pages 610-619

  Cosset, J M ^a   Haie Meder, C ^b  

^a INSTITUT CURIE   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Brachytherapy; High dose rate; Low dose rate; Prostate cancer

Indexed keywords

BRACHYTHERAPY; CANCER LOCALIZATION; CANCER RISK; FINANCIAL MANAGEMENT; HEALTH ECONOMICS; HUMAN; MONOTHERAPY; PATIENT POSITIONING; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION PROTECTION; RADIOBIOLOGY; REIMBURSEMENT; REVIEW; TREATMENT PLANNING;

EID: 29144530142     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2005.09.019     Document Type: Article

References (63)

1. A.G. Anastasiadis, M.A. Ghafar, L. Salomon, F. Vacherot, P. Benedit, and M.W. Chen Human hormone-refractory prostate cancers can harbor mutations in the O(2)-dependent degradation domain of hypoxia inducible factor-1alpha (HIF-1alpha) J. Cancer Res. Clin. Oncol. 128 2002 358 362
2. J.N. Aronowitz Dawn of prostate brachytherapy: 1915-1930 Int. J. Radiat. Oncol. Biol. Phys. 1 2002 712 718
3. J.J. Batermann Brachytherapy as monotherapy in localised prostate cancer, permanent seed implantation or high dose rate? Radiother. Oncol. 71 2004 S29 [abstract]
4. D. Beyer Permanent seed implantation: the proven choice for your patient [abstract]. Radiother. Oncol. 71 suppl. 2004 S30
5. M. Bolla, L. Collette, L. Blank, P. Warde, J.B. Dubois, and R.O. Mirimanoff Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial Lancet 13 2002 103 106
6. D.J. Brenner, and E.J. Hall Fractionation and protraction for radiotherapy of prostate carcinoma Int. J. Radiat. Oncol. Biol. Phys. 15 1999 1095 1101
7. D.J. Brenner, A.A. Martinez, G.K. Edmundson, C. Mitchell, H.D. Thames, and E.P. Armour Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue Int. J. Radiat. Oncol. Biol. Phys. 1 2002 6 13
8. C. Buron, L. Chauveinc, N. Salem, D. Peiffert, P. Pommier, and M. Delannes An economic evaluation of interstitial brachytherapy, radical prostatectomy and external beam radiotherapy for localized prostate cancer: results during the first year after therapy Radiother.Oncol. 71 2004 S36
9. R. Chappell, J. Fowler, and M. Ritter New data on the value of alpha/beta-evidence mounts that it is low Int. J. Radiat. Oncol. Biol. Phys. 1 2004 1002 1003
10. D. Chassagne, B. Court, A. Gerbaulet, J.L. Perrin, and C. Haie Cancer of the prostate: technics of curietherapy. Review of the literature and experience at the institut Gustave-Roussy Bull. Cancer 72 1985 578 584
11. J.M. Cosset, M. Henry-Amar, T. Girinski, E. Malaise, N. Dupouy, and J. Dutreix Late toxicity of radiotherapy in Hodgkin's disease. The role of fraction size Acta Oncol. 27 1988 123 129
12. J.M. Cosset, L. Pinillos-Ashton, F. Mettler Comite 3 (radioprotection en ḿdecine) de la Commission internationale de protection radiologique The recommendations of the International Commission on Radiological Protection (ICRP) for high-dose rate brachytherapy and for permanent prostatic implants Cancer Radiother. 1 2004 S50 S55
13. J. Crook Commentary on "a comparison of the precision of seeds deposited as loose seeds vs. suture-embedded seeds: a randomized trial" and "prostate brachytherapy seed migration and dosimetry: analysis of stranded sources and other potential predictive factors": to strand or not to strand-is this really the question? Brachytherapy. 3 2004 20 21
14. S.J. Damore, A.M. Syed, A.A. Puthawala, and A. Sharma Needle displacement during HDR brachytherapy in the treatment of prostate cancer Int. J. Radiat. Oncol. Biol. Phys. 15 2000 1205 1211
15. J. Denekamp, T. Waites, and J.F. Fowler Predicting realistic RBE values for clinically relevant radiotherapy schedules Int. J. Radiat. Biol. 71 1997 681 694
16. B. Dubray, M. Henry-Amar, J.H. Meerwaldt, E.M. Noordijk, D.O. Dixon, and J.M. Cosset Radiation-induced lung damage after thoracic irradiation for Hodgkin's disease: the role of fractionation Radiother. Oncol. 36 1995 211 217
17. G.M. Duchesne, and L.J. Peters What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose rate brachytherapy Int. J. Radiat. Oncol. Biol. Phys. 1 1999 747 748
18. J. Dutreix, J.M. Cosset, and T. Girinsky Biological equivalency of high single doses used in intraoperative irradiation Bull. Cancer Radiother. 77 1990 125 134
19. P. Eiffel High-dose rate brachytherapy for carcinoma of the cervix: high tech or high risk? Int. J. Radiat. Oncol. Biol. Phys. 24 1992 383 386
20. J. Fowler Dose reduction factors when increasing dose rate in LDR or MDR brachytherapy of carcinoma of the cervix Radiother. Oncol. 45 1997 49 54
21. J.F. Fowler Is HDR brachytherapy for carcinoma of the uterine cervix high-throughput but high risk? Acta Oncol. 37 1998 113 115
22. J. Fowler, R. Chappell, and M. Ritter Is alpha/beta for prostate tumors really low? Int. J. Radiat. Oncol. Biol. Phys. 15 2001 1021 1031
23. J.F. Fowler, M.A. Ritter, R.J. Chappell, and D.J. Brenner What hypofractionated protocols should be tested for prostate cancer? Int. J. Radiat. Oncol. Biol. Phys. 15 2003 1093 1104
24. R.M. Galalae, A. Martinez, T. Mate, C. Mitchell, G. Edmundson, and N. Nuernberg Long-term outcome by risk factors using conformal high-dose rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer Int. J. Radiat. Oncol. Biol. Phys. 15 2004 1048 1055
25. D. Gallez-Marchal, M. Fayolle, M. Henry-Amar, J.P. Le Bourgeois, P. Rougier, and J.M. Cosset Radiation injuries of the gastrointestinal tract in Hodgkin's disease: the role of exploratory laparotomy and fractionation. A study of 19 cases observed in a series of 134 patients treated at the institut Gustave-Roussy from 1972 to 1982 Radiother. Oncol. 2 1984 93 99
26. I.S. Grills, A.A. Martinez, M. Hollander, R. Huang, K. Goldman, and P.Y. Chen High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low-dose rate palladium seeds J. Urol. 171 2004 1098 1104
27. B. Guix, J.M. Bartrina, R. Serrate, J.I. Tello, J.R. Vendrell, and I. Henriquez Quality assurance in HDR brachytherapy for prostate cancer: how can prostate displacement be minimized? [abstract]. Radiother. Oncol. 71 suppl. 2004 S109
28. C. Haie-Meder, A. Kramar, P. Lambin, R. Lancar, P. Scalliet, and J. Bouzy Analysis of complications in a prospective randomized trial comparing two brachytherapy low-dose rates in cervical carcinoma Int. J. Radiat. Oncol. Biol. Phys. 29 1994 953 960
29. M. Hareyama, K. Sakata, A. Oouchi, H. Nagakura, M. Shido, and K. Koito High-dose rate vs low-dose rate intracavitary therapy for cervix cancer: a randomized trial Cancer 94 2002 117 124
30. H.H. Holm, N. Juul, and J.F. Pederson Transperineal I-125 seed implantation in prostatic cancer guided by transrectal ultrasonography J. Urol. 130 1983 283 286
31. Y. Jo, J. Hiratsuka, T. Fujii, A. Takenaka, and M. Fujisawa High-dose rate iridium-192 afterloading therapy combined with external beam radiotherapy for T1c-T3bN0M0 prostate cancer Urology 64 2004 556 560
32. F. Joly, D. Brune, J.E. Couette, F. Lesaunier, J.F. Heron, and J. Peny Health-related quality of life and sequelae in patients treated with brachytherapy and external beam irradiation for localized prostate cancer Ann. Oncol. 9 1998 751 757
33. L.L. Kestin, A.A. Martinez, J.S. Stromberg, G.K. Edmundson, G.S. Gustafson, D.S. Brabbins, and P.Y. Chen Matched-pair analysis of conformal high-dose rate brachytherapy boost vs external-beam radiation therapy alone for locally advanced prostate cancer J. Clin. Oncol. 18 2000 2869 2880
34. C.R. King, and C.S. Mayo Is the prostate alpha/beta ratio of 1.5 from Brenner & Hall a modeling artifact Int. J. Radiat. Oncol. Biol. Phys 1 2000 536 539
35. C.R. King, and J.F. Fowler A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low Int. J. Radiat. Oncol. Biol. Phys 51 2001 213 214
36. C.R. King LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models Brachytherapy. 1 2002 219 226
37. M.A. Kollmeier, R.G. Stock, and N. Stone Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality Int. J. Radiat. Oncol. Biol. Phys. 1 2003 645 653
38. G. Kovacs, R. Potter, T. Loch, J. Hammer, I.K. Kolkman-Deurloo, and J.J. de la Rosette GEC-ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer Radiother. Oncol. 74 2005 137 148
39. F. Leborgne, J.F. Fowler, J.H. Leborgne, E. Zubizarreta, and R. Chappell Biologically effective doses in medium dose rate brachytherapy of cancer of the cervix Radiat. Oncol. Investig. 5 1997 289 299
40. P. Lertsanguansinchai, C. Lertbutsayanukul, K. Shotelersuk, C. Khorprasert, P. Rojpornpradit, and T. Chottetanaprasith Phase III randomized trial comparing LDR and HDR brachytherapy in treatment of cervical carcinoma Int. J. Radiat. Oncol. Biol. Phys. 59 2004 1424 1431
41. A.A. Martinez, I. Pataki, G. Edmundson, E. Sebastian, D. Brabbins, and G. Gustafson Phase II prospective study of the use of conformal high-dose rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report Int. J. Radiat. Oncol. Biol. Phys. 1 2001 61 69
42. A.A. Martinez, G. Gustafson, J. Gonzalez, E. Armour, C. Mitchell, and G. Edmundson Dose escalation using conformal high-dose rate brachytherapy improves outcome in unfavorable prostate cancer Int. J. Radiat. Oncol. Biol. Phys. 1 2002 316 327
43. E. Mullokandov, and G. Gejerman Analysis of serial CT scans to assess template and catheter movement in prostate HDR brachytherapy Int. J. Radiat. Oncol. Biol. Phys. 15 2004 1063 1071
44. S. Nag, C. Chao, B. Erickson, J. Fowler, N. Gupta, and A. Martinez The American Brachytherapy Society recommendations for low-dose rate brachytherapy for carcinoma of the cervix Int. J. Radiat. Oncol. Biol. Phys. 52 2002 33 48 (Jan 1)
45. A.E. Nahum, B. Movsas, E.M. Horwitz, C.C. Stobbe, and J.D. Chapman Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio Int. J. Radiat. Oncol. Biol. Phys. 1 2003 391 401
46. C. Orton, M. Seyedsadr, and A. Somnay Comparison of high and low-dose rate remote afterloading for cervix cancer and the importance of fractionation Int. J. Radiat. Oncol. Biol. Phys. 21 1991 1425 1434
47. Orton CG. In regard to Nahum et al. (Int J Radiat Oncol Biol Phys 2003;57:391-401):: incorporating clinical measurements of hypoxia into tumor control modeling of prostate cancer: implications for the alpha/beta ratio. Int. J. Radiat. Oncol. Biol. Phys. 2004 1:1637.
48. O. Pasteau, and P. Degrais De l'emploi du Radium dans les cancers de la prostate J.Urol. 1913 341 345
49. F.D. Patel, S.C. Sharma, P.S. Negi, S. Ghoshal, and B.D. Gupta Low-dose rate vs. high-dose rate brachytherapy in the treatment of carcinoma of the uterine cervix: a clinical trial Int. J. Radiat. Oncol. Biol. Phys. 28 1994 335 341
50. D.G. Petereit, J.F. Fowler, and T.J. Kinsella Optimizing the dose rate and technique in cervical carcinoma - balancing cases vs complications Int. J. Radiat. Oncol. Biol. Phys. 30 1994 1195 1197
51. M.V. Pilepich, K. Winter, C.A. Lawton, R.E. Krisch, H.B. Wolkov, and B. Movsas Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31 Int. J. Radiat. Oncol. Biol. Phys. 1 2005 1285 1290
52. P. Pommier, A. Villers, A. Bataillard, D. Brune, B. Fervers, J.M. Bachaud, and Berger Standards, Options, and Recommendations for brachytherapy in patients with prostate cancer: efficacy and toxicity Cancer Radiother. 5 2001 770 786
53. L. Potters, C. Morgenstern, E. Calugaru, P. Fearn, A. Jassal, and J. Presser 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer J. Urol. 173 2005 1562 1566
54. Y. Shigematsu, K. Nishiyama, N. Masaki, T. Inoue, Y. Miyata, and H. Ikeda Treatment of carcinoma of the uterine cervix by remotely controlled afterloading intracavitary radiotherapy with high-dose rate: a comparative study with a low-dose rate system Int. J. Radiat. Oncol. Biol. Phys. 9 1983 351 356
55. P. Sminia, C.J. Schneider, and J.F. Fowler The optimal fraction size in high-dose rate brachytherapy: dependency on tissue repair kinetics and low-dose rate Int. J. Radiat. Oncol. Biol. Phys. 1 2002 844 849
56. R.G. Stock, O. Cahlon, J.A. Cesaretti, M.A. Kollmeier, and N.N. Stone Combined modality treatment in the management of high-risk prostate cancer Int. J. Radiat. Oncol. Biol. Phys. 1 2004 1352 1359
57. J.E. Sylvester, J.C. Blasko, P.D. Grimm, R. Meier, and J.A. Malmgren Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience Int. J. Radiat. Oncol. Biol. Phys. 15 2003 944 952
58. J.E. Sylvester, J.C. Blasko, P.D. Grimm, R. Meier, and J.A. Malmgren Prostate cancer patients treated with external beam radiation combined with I125/Pd103 brachytherapy: Seattle fifteen year outcome results Radiother. Oncol. 71 2004 S17 [abstract]
59. H.D. Thames, and J.H. Hendry Fractionation in Radiotherapy 1987 Taylor and Francis London
60. F.A. Vicini, L.L. Kestin, and A.A. Martinez Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation Tech. Urol. 6 2000 135 145
61. F.A. Vicini, C. Vargas, G. Edmundson, L. Kestin, and A. Martinez The role of high-dose rate brachytherapy in locally advanced prostate cancer Semin. Radiat. Oncol. 13 2003 98 108
62. F. Vicini, C. Vargas, G. Gustafson, G. Edmundson, and A. Martinez High-dose rate brachytherapy in the treatment of prostate cancer World J. Urol. 21 2003 220 228
63. T. Wahlgren, Y. Brandberg, L. Haggarth, M. Hellstrom, and S. Nilsson Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with (192)ir brachytherapy: a prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25 Int. J. Radiat. Oncol. Biol. Phys. 1 2004 51 59